VePesid

(etoposide)

ApprovedSmall molecule

Etoposide is a chemotherapy drug used to treat certain types of cancer, including lung cancer, testicular cancer, and lymphomas, by stopping cancer cells from dividing and growing.[2] VePesid is currently approved and in use across 136 indications[4].[1]

VePesid is one of 1160 small molecule programs targeting Seminoma. It is currently in Approved.

136

Indications

1,142

Total Trials

Active Trials

1,159

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

SeminomaActive, not recruiting

LeukemiaCompleted

Diffuse Large B-Cell LymphomaCompleted

Multiple MyelomaActive, not recruiting

Lung CancerUnknown status

ChemotherapyCompleted

RemissionActive, not recruiting

Acute Myeloid LeukemiaCompleted

Pancreatic CancerApproved

Central Nervous System NeoplasmApproved

SeminomaPhase 2

Active, not recruiting

LeukemiaPhase 3

Completed

Diffuse Large B-Cell LymphomaPhase 3

Completed

Multiple MyelomaPhase 3

Active, not recruiting

Lung CancerApproved

Unknown status

ChemotherapyPhase 3

Completed

RemissionPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Completed

Pancreatic CancerApproved

Approved

Central Nervous System NeoplasmApproved

Approved

Showing 10 of 136 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

VePesid

AAvyxa

Approved

14 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

Lexiscan

Astellas

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT00077285

Phase 1/2Recruiting

SCLC

NCT07136285

Phase 2Recruiting

Chemotherapy

NCT06536868

Q1 2027

Phase 1/2Active, not recruiting

Acute Lymphoblastic Leukemia

NCT05192889

Phase 1/2Recruiting

Neuroendocrine Carcinoma

NCT06157827

Q2 2027

Phase 1/2Active, not recruiting

Acute Myeloid Leukemia

NCT03793478

Clinical

Trials by Indication[1]

Lymphoma36 trials

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00049595·552 enrolled

Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

Completed·SStanford University·Phase 2·NCT00026208·76 enrolled

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00505921·27 enrolled

Show 33 more trials

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07097363·18 enrolled

Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Completed·—·Phase 1·NCT01476839·25 enrolled

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed·TTemple University·Phase 1/2·NCT00002510

CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT03579927

A Phase II Study VEPEMB In Patients With Hodgkin's Lymphoma Aged ≥ 60 Years

Completed·NNewcastle-upon-Tyne Hospitals NHS Trust·Phase 2·NCT00079105·175 enrolled

S0410 Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00233987·98 enrolled

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00002697

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00967369·20 enrolled

Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin's Lymphoma

Completed·—·Phase 2·NCT00049439·54 enrolled

Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy

Unknown status·OOttawa Regional Cancer Centre·Phase 2·NCT00002488

Combination Chemotherapy in Treating Patients With Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00002835·116 enrolled

Tandem Auto-Allo Transplant for Lymphoma

Completed·MMassachusetts General Hospital·Phase 2·NCT01181271·42 enrolled

SIMPLE Chemotherapy for NK Lymphoma/Leukaemia

Unknown status·TThe University of Hong Kong·Phase 3·NCT03623087·68 enrolled

Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1·NCT00101205·40 enrolled

Study Comparing ABVD vs BEACOPP in Advanced Hodgkin's Lymphoma

Completed·FFondazione Michelangelo·Phase 3·NCT01251107·331 enrolled

Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00032019·78 enrolled

Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant

Completed·—·Phase 1·NCT01959477·33 enrolled

Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.

Unknown status·PPETHEMA Foundation·Phase 2·NCT05049473·100 enrolled

CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma

Terminated·—·Phase 2·NCT01746173·5 enrolled

Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT00352027·81 enrolled

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma

Completed·SSoonchunhyang University Hospital·Phase 2·NCT03794167·75 enrolled

S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00109928·34 enrolled

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT01097057·20 enrolled

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT03019640·22 enrolled

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT03864419·18 enrolled

Combination Chemotherapy in Treating Children With Lymphoma

Completed·CChildren's Oncology Group·Phase 2·NCT00002590·221 enrolled

DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Unknown status·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT03837873·118 enrolled

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Unknown status·—·Phase 1/2·NCT05776407·12 enrolled

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01169636·62 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00049036·106 enrolled

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

Completed·WWeill Medical College of Cornell University·Phase 1/2·NCT02059239·34 enrolled

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE

Completed·TThe Lymphoma Academic Research Organisation·Phase 1/2·NCT02686346·53 enrolled

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00005803·76 enrolled

Small Cell Lung Cancer24 trials

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Not yet recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06648200·100 enrolled

Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer

Recruiting·FFundación GECP·Phase 2·NCT05384015·46 enrolled

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Terminated· Roche logo

Roche·Phase 1·NCT04422210·2 enrolled

Show 21 more trials

SKB500 Combinations in Patients With Small Cell Lung Cancer

Not yet recruiting·SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.·Phase 2·NCT07296809·80 enrolled

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

Not yet recruiting·FFujian Cancer Hospital·Phase 2·NCT06786312·34 enrolled

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00079040·65 enrolled

R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00544596·27 enrolled

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05224141·460 enrolled

Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer

Not yet recruiting·TThe Second Affiliated Hospital of Dalian Medical University·Phase 2·NCT07349225·46 enrolled

LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer

Active, not recruiting·—·Phase 1·NCT04560972·3 enrolled

Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·—·Phase 2·NCT00083161·8 enrolled

S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer

Terminated·SSWOG Cancer Research Network·Phase 2·NCT00045617·9 enrolled

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04234607·738 enrolled

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003299·587 enrolled

A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 1·NCT05026593·60 enrolled

Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer

Completed·HHoosier Cancer Research Network·Phase 2·NCT00613626·74 enrolled

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT03850067·90 enrolled

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT03382561·160 enrolled

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Recruiting·SShanghai Pulmonary Hospital, Shanghai, China·Phase 2·NCT06256237·30 enrolled

Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer

Recruiting·YYunpeng Liu·N/A·NCT06480864·38 enrolled

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT04696575·28 enrolled

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00453154·156 enrolled

Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer

Terminated·GGiuseppe Giaccone·Phase 1/2·NCT02748889·1 enrolled

QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer

Terminated·NNantCell, Inc.·Phase 1/2·NCT00791154·213 enrolled

Acute Myeloid Leukemia14 trials

Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101)

Terminated·UUniversity of Florida·Phase 1/2·NCT02773732·11 enrolled

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Completed·UUniversity of Ulm·Phase 3·NCT00146120·400 enrolled

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Completed·—·Phase 1·NCT01127009·3 enrolled

Show 11 more trials

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01371981·1,645 enrolled

Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00666588·52 enrolled

IV Plerixafor With Mitoxantrone Etoposide and Cytarabine for Acute Myeloid Leukemia (AML)

Terminated·WWashington University School of Medicine·Phase 1·NCT01027923·6 enrolled

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00112853·100 enrolled

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·SStanford University·Phase 1·NCT01904643·17 enrolled

Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003190·640 enrolled

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·UUniversity of Ulm·Phase 2/3·NCT00151242·920 enrolled

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT00906945·39 enrolled

AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia

Completed·WWashington University School of Medicine·Phase 1/2·NCT00512252·52 enrolled

Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Terminated·FFred Hutchinson Cancer Center·Phase 1/2·NCT01342887·6 enrolled

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT03793478·65 enrolled

Acute Lymphoblastic Leukemia8 trials

Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 3·NCT00002816·120 enrolled

Combination Chemotherapy, Bone Marrow Transplantation, and Radiation Therapy in Treating Infants With Acute Lymphoblastic Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00002785

Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00427791·23 enrolled

Show 5 more trials

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT00058461·82 enrolled

Risk-Adjusted Combination Chemotherapy in Treating Young Patients With Acute Lymphoblastic Leukemia

Unknown status·—·Phase 3·NCT00764907·4,000 enrolled

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Completed·CChildren's Oncology Group·Phase 1/2·NCT00098839·134 enrolled

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 1/2·NCT05192889·35 enrolled

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Completed·—·Phase 1/2·NCT00576979·51 enrolled

Neuroblastoma6 trials

Response-based Treatment of High-risk Neuroblastoma

Unknown status·SSamsung Medical Center·Phase 2·NCT02771743·54 enrolled

Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas

Completed·—·Phase 2·NCT00165139·20 enrolled

High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)

Recruiting·SSt. Anna Kinderkrebsforschung·Phase 3·NCT01704716·3,300 enrolled

Show 3 more trials

Tandem High Dose Chemotherapy With 131I-MIBG Treatment in High Risk Neuroblastoma

Unknown status·SSamsung Medical Center·Phase 2·NCT03061656·40 enrolled

High-Risk Neuroblastoma Chemotherapy Without G-CSF

Completed·—·N/A·NCT02786719·13 enrolled

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00499616·464 enrolled

70 more indications

Diffuse Large B-Cell Lymphoma5 trials

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT01197560·111 enrolled

Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Completed·CC. Babis Andreadis·Phase 2·NCT01555541·19 enrolled

Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma

Withdrawn·FFred Hutchinson Cancer Center·Phase 1·NCT05228249

Show 2 more trials

Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma

Terminated· Pfizer logo

Pfizer·Phase 2·NCT02592876·81 enrolled

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Unknown status·BBeBetter Med Inc·Phase 1·NCT06164327·75 enrolled

Osteosarcoma4 trials

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00023998·80 enrolled

Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma

Completed·CChildren's Oncology Group·Phase 3·NCT00134030·1,334 enrolled

A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Completed· Eisai logo

Eisai·Phase 2·NCT04154189·81 enrolled

Show 1 more trial

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Completed· Eisai logo

Eisai·Phase 1/2·NCT02432274·117 enrolled

Germ Cell Tumor4 trials

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Completed·UUNICANCER·Phase 3·NCT00104676·263 enrolled

Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary Central Nervous System (CNS) Germ Cell Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00085098·24 enrolled

Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 2·NCT00047320·104 enrolled

Show 1 more trial

Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors

Completed·CChildren's Oncology Group·Phase 3·NCT00053352·302 enrolled

Ovarian Cancer4 trials

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

Not yet recruiting·FFudan University·Phase 2·NCT07117877·33 enrolled

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Completed·SSun Yat-sen University·Phase 2·NCT02867956·35 enrolled

Show 1 more trial

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

Completed·CChipscreen Biosciences, Ltd.·Phase 2·NCT03901118·47 enrolled

Treatment4 trials

L-DEP as an Initial Treatment for EBV-HLH

Unknown status·—·Phase 3·NCT02912702·120 enrolled

Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT01435018·334 enrolled

Optimal Treatment Strategy Based on for Pediatric AML

Unknown status·SSamsung Medical Center·Phase 2·NCT02848183·350 enrolled

Show 1 more trial

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Terminated·TTufts Medical Center·Phase 3·NCT01014767·27 enrolled

Chemotherapy4 trials

Low-dose Radiotherapy Combined with Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC

Not yet recruiting·SSichuan University·Phase 1·NCT06732258·12 enrolled

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Completed·AArog Pharmaceuticals, Inc.·Phase 1/2·NCT02626338·16 enrolled

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

Unknown status·TTaizhou Hospital·Phase 2·NCT04363255·20 enrolled

Show 1 more trial

Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC

Recruiting·SSecond Hospital of Shanxi Medical University·Phase 2·NCT06536868·40 enrolled

Lymphoid Malignancies4 trials

Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00536978·22 enrolled

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

Completed·—·Phase 1·NCT00691210·40 enrolled

Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00472056·93 enrolled

Show 1 more trial

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT01921387·20 enrolled

Hodgkin's Disease3 trials

Combination Chemotherapy in Treating Patients With AIDS-Related Hodgkin's Disease

Completed·—·Phase 2·NCT00003114·5 enrolled

Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

Terminated·SStanford University·Phase 2·NCT00225173·45 enrolled

Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease

Completed·CChildren's Oncology Group·Phase 3·NCT00002827·294 enrolled

Patients With Advanced Solid Tumors3 trials

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00027898·27 enrolled

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Leukemia3 trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Completed·UUniversity of Nebraska·Phase 2·NCT00002638·30 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 3·NCT00002766·170 enrolled

Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia

Terminated·—·Phase 1·NCT02631252·1 enrolled

Hematologic Cancer2 trials

Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·SScripps Health·Phase 2·NCT00003269·20 enrolled

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT00304018·5 enrolled

Prognosis2 trials

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099188·27 enrolled

Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT02099175·41 enrolled

Breast Cancer2 trials

Combination Chemotherapy in Treating Patients With Metastatic Breast Cancer

Completed·—·Phase 2·NCT00006260·36 enrolled

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

Terminated·MMedstar Health Research Institute·Phase 2·NCT00810017·2 enrolled

Prostate Cancer2 trials

A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·N/A·NCT01084759·16 enrolled

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00514540·121 enrolled

Primitive Neuroectodermal Tumor2 trials

Combination Chemotherapy Followed by Second-Look Surgery and Radiation Therapy in Treating Children With Nonmetastatic Medulloblastoma or Primitive Neuroectodermal Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00006461·82 enrolled

Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00336024·91 enrolled

Conditioning2 trials

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03385096·122 enrolled

BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT

Unknown status·NNanfang Hospital, Southern Medical University·Phase 2/3·NCT03733327·20 enrolled

Stem Cell Transplantation2 trials

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004061·111 enrolled

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Unknown status·UUniversity of Leicester·Phase 3·NCT00020566·1,200 enrolled

Rhabdomyosarcoma2 trials

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00077285·65 enrolled

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Combination Therapy2 trials

Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00006047·44 enrolled

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT06030258·120 enrolled

Non-Small Cell Lung Cancer2 trials

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Terminated·UUniversity of Washington·Phase 1·NCT01411098·6 enrolled

Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 2·NCT01822496·59 enrolled

Retinoblastoma2 trials

Alternating Systemic Chemotherapy and Intra-Arterial Melphalan (IAM) Chemotherapy in Children With Intra-Ocular Retinoblastoma

Terminated·UUniversity of California, San Francisco·Phase 1·NCT02116959·6 enrolled

Systemic Chemotherapy and Subtenon Carboplatin, and Local Ophthalmic Therapy in Children With Intraocular Retinoblastoma

Completed·CChildren's Oncology Group·Phase 3·NCT00072384·30 enrolled

Medulloblastoma2 trials

Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma

Completed·CChildren's Oncology Group·Phase 2·NCT00003573·53 enrolled

Low-Dose Radiation and Combination Chemotherapy Following Surgery in Children With Newly Diagnosed Medulloblastoma

Terminated·—·Phase 2·NCT00031590·30 enrolled

Seminoma2 trials

Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma

Active, not recruiting·SSwiss Cancer Institute·Phase 2·NCT03937843·135 enrolled

Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 2·NCT01887340·271 enrolled

Anaplastic Large Cell Lymphoma2 trials

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01979536·137 enrolled

Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00354107·5 enrolled

Phase 11 trial

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Terminated·OOncoMed Pharmaceuticals, Inc.·Phase 1/2·NCT01859741·172 enrolled

Lymphoproliferative Disorder1 trial

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Recruiting·JJennifer Amengual·Phase 2·NCT06954805·30 enrolled

Waldenstrom macroglobulinemia1 trial

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT00723658

Bone Marrow Transplantation1 trial

High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00060255·451 enrolled

Graft Versus Host Disease1 trial

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Completed·MMassachusetts General Hospital·Phase 1·NCT00513474·46 enrolled

Recurrent or Refractory1 trial

Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT04530487·1 enrolled

Refractory Solid Tumors1 trial

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT03420963·12 enrolled

Gestational Trophoblastic Tumor1 trial

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Unknown status·WWeiguo Lv·Phase 3·NCT02639650·214 enrolled

Advanced Solid Tumors1 trial

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT00960063·4 enrolled

Brain Cancer1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003309·33 enrolled

B-cell Malignancies1 trial

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Completed· Incyte logo

Incyte·Phase 1/2·NCT02018861·88 enrolled

AIN1 trial

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Recruiting·IIndiana University·Phase 1/2·NCT06937866·38 enrolled

Neoadjuvant Treatment1 trial

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Not yet recruiting·—·Phase 2·NCT06375109·60 enrolled

Malignant Solid Tumors1 trial

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT07268040·400 enrolled

Neuroendocrine Carcinoma1 trial

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 1/2·NCT06157827·178 enrolled

Myeloid Malignancies1 trial

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Terminated· Gilead logo

Gilead·Phase 2·NCT04778410·54 enrolled

Adult Medulloblastoma1 trial

Interest of a Dose Decrease for Radiotherapy Associated With Chemotherapy for Treatment of Standard Risk Adult Medulloblastomas

Unknown status·—·Phase 2·NCT01857453·97 enrolled

Malignant Peripheral Nerve Sheath Tumor1 trial

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00304083·48 enrolled

Myeloproliferative Disorder1 trial

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00357305·25 enrolled

Hypofractionated Radiotherapy1 trial

Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC

Withdrawn·TThe Netherlands Cancer Institute·Phase 2·NCT02947113

Soft Tissue Sarcoma1 trial

Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

Unknown status·SSamsung Medical Center·Phase 2·NCT02784015·41 enrolled

Ependymoma1 trial

Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

Active, not recruiting·CChildren's Oncology Group·Phase 3·NCT01096368·479 enrolled

Stem Cell Transplant1 trial

High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors

Completed·RRoswell Park Cancer Institute·N/A·NCT00536601·174 enrolled

Relapsed/Refractory1 trial

Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06489808·89 enrolled

T-cell non-Hodgkin lymphoma1 trial

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

Completed·—·Phase 1·NCT02342782·20 enrolled

Maximum Tolerated Dose1 trial

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT00537511·22 enrolled

Multiple Myeloma1 trial

Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma

Completed·OOHSU Knight Cancer Institute·Phase 1·NCT02504359·11 enrolled

Unilateral Retinoblastoma1 trial

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

Active, not recruiting·IInstitut Curie·Phase 2·NCT02870907·195 enrolled

Central Nervous System Lymphoma1 trial

A Trial to Compare Ibrutinib Versus Lenalidomide in Combination With MRE-chemotherapy for Adult Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT04129710·120 enrolled

Neuroendocrine Neoplasm1 trial

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

Completed·GGrupo Espanol de Tumores Neuroendocrinos·Phase 2·NCT03980925·37 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL

Unknown status·RRuijin Hospital·N/A·NCT05863845·52 enrolled

Histiocytosis1 trial

Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02385110·18 enrolled

Brain Metastases1 trial

Valproate and Etoposide for Patients With Neuronal Tumors and Brain Metastases

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00513162·8 enrolled

B-cell Lymphoid Malignancies1 trial

Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies

Active, not recruiting·MMedical College of Wisconsin·Phase 1·NCT05270057·11 enrolled

Adult Acute Lymphoblastic Leukemia1 trial

Chemotherapy With Liposomal Cytarabine CNS Prophylaxis for Adult Acute Lymphoblastic Leukemia & Lymphoblastic Lymphoma

Terminated·UUniversity of California, San Diego·Phase 2·NCT02043587·31 enrolled

Transplantation1 trial

High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML

Completed·UUniversity of Chicago·Phase 2·NCT00774046·32 enrolled

Advanced Stage1 trial

HD21 for Advanced Stages

Active, not recruiting·UUniversity of Cologne·Phase 3·NCT02661503·1,500 enrolled

Myelodysplastic Syndrome1 trial

Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·CChildren's Oncology Group·Phase 2·NCT00002805·115 enrolled

First-line Treatment1 trial

Etoposide in the First-line Treatment of Adult EBV-HLH

Unknown status·—·Phase 3·NCT03742115·90 enrolled

Lymphoblastic Lymphoma1 trial

NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

Completed·SSt. Jude Children's Research Hospital·Phase 2·NCT01451515·23 enrolled

Age1 trial

HD11 for Intermediate Stages

Completed·UUniversity of Cologne·Phase 3·NCT00264953·1,395 enrolled

Chemoradiotherapy1 trial

Chemoradiotherapy With or Without Sintilimab in Limited-stage SCLC

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04189094·140 enrolled

Newly Diagnosed1 trial

Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma

Withdrawn·CChildren's Oncology Group·Phase 3·NCT00334867

Glioma1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma

Completed·CChildren's Oncology Group·Phase 1·NCT00003625·7 enrolled

SCLC1 trial

Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Recruiting·NNewsoara HYK Biopharmaceutical (Shanghai) Co., Ltd.·Phase 1/2·NCT07136285·27 enrolled

Lung Cancer1 trial

Phase 1b/2 Study of Carfilzomib, Carboplatin, and Etoposide in Patients With Previously Untreated Extensive Stage Small-cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT01987232·32 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 10, 1983

VEPESID

NDA NDA018768

Dec 30, 1986

VEPESID

NDA NDA019557

Dec 30, 1986

VEPESID

NDA NDA019557

Mar 26, 1987

VEPESID

NDA NDA019557

May 20, 1987

VEPESID

NDA NDA019557

Aug 24, 1987

VEPESID

NDA NDA019557

Aug 24, 1987

VEPESID

NDA NDA019557

Jan 25, 1988

VEPESID

NDA NDA019557

Jul 14, 1989

VEPESID

NDA NDA019557

Nov 1, 1991

VEPESID

NDA NDA019557

Nov 1, 1991

VEPESID

NDA NDA019557

Mar 2, 1993

VEPESID

NDA NDA019557

Jul 23, 1993

VEPESID

NDA NDA019557

May 17, 1995

VEPESID

NDA NDA019557

Oct 17, 1995

VEPESID

NDA NDA019557

May 17, 1996

ETOPOPHOS PRESERVATIVE FREE

NDA NDA020457

Feb 27, 1998

ETOPOPHOS PRESERVATIVE FREE

NDA NDA020906

Dec 15, 1998

VEPESID

NDA NDA019557

Jan 19, 1999

VEPESID

NDA NDA019557

Apr 2, 1999

VEPESID

NDA NDA019557

Feb 2, 2000

VEPESID

NDA NDA019557

Nov 21, 2000

VEPESID

NDA NDA019557

Nov 5, 2002

VEPESID

NDA NDA019557

Feb 13, 2026

AVOPEF

NDA NDA220200

Sources

References

[1]
ClinicalTrials.gov — 1142 trial records for etoposide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — VePesid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — etoposide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for etoposide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA220200). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Avyxa company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase II Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AAvyxa